Objective Lupus nephritis (LN) is a major cause of morbidity and mortality, affecting up to 60% of patients with systemic lupus erythematosus (SLE). The perspectives of patients with SLE have been ...

Describe why combination of anticoagulation and corticosteroids is the cornerstone treatment of CAPS and that life-threatening CAPS episodes should be treated with a triple-therapy including ...

Objective Anifrolumab is a fully human immunoglobulin G 1 κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe ...

Objective To evaluate safety and mechanism of action of mezagitamab (TAK-079), an anti-CD38 monoclonal antibody, in patients with moderate to severe systemic lupus erythematosus (SLE). Methods A phase ...

Objective Hydroxychloroquine (HCQ) is an antimalarial drug employed in the treatment of systemic lupus erythematosus (SLE). Prior studies reported inconsistent results regarding the association ...

Background Some countries face restrictions to prescribe Chloroquine (CQ) and Hydroxychloroquine (HCQ) during pregnancy, due to report of ocular toxicity in rodents and potential genotoxicity. The aim ...

1 Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Republic of Korea 2 Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, ...

Background and aims IFIT3 is one of the Interferon-stimulated genes showed significantly increase in PBMCs of SLE patients. However, the functions of IFIT3 in dysregulated immune responses of SLE are ...

1 West China Hospital affiliated Sichuan University, Department of Laboratory Medicine, Chengdu, China 2 West China Hospital affiliated Sichuan University, Department of Rheumatology, Chengdu, China 3 ...

Objectives Chorea, characterised by involuntary, irregular movements, is a rare neurological manifestation of antiphospholipid syndrome (APS). The specific clinical features remain unclear. This study ...

Background The short-term and long-term outcome of inflammatory neuropsychiatric SLE (NPSLE) with immunosuppressive treatment is largely unknown. We used clinical data from our tertiary referral ...